Jason Eric Perry

US Patent:

20120238552, Sep 20, 2012

Filed:

Mar 19, 2012

Appl. No.:

13/423606

Inventors:

Jason M. PERRY - Cambridge MA, US
Daniel R. DEAVER - Franklin MA, US
Magall B. HICKEY - Medford MA, US
Julius F. REMENAR - Framingham MA, US
Jennifer VANDIVER - Arlington MA, US

Assignee:

ALKERMES, INC. - Waltham MA

International Classification:

A61K 31/496
A61P 25/24
A61P 25/00
A61P 25/22
A61K 31/5513
A61P 25/18

US Classification:

514220, 51425307

Abstract:

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

US Patent:

20210205302, Jul 8, 2021

Filed:

Mar 24, 2021

Appl. No.:

17/211352

Inventors:

- Dublin, IE
Tarek A. Zeidan - Lexington MA, US
Renato A. Chiarella - Cambridge MA, US
Steven G. Wright - Madeira OH, US
Jason M. Perry - Cambridge MA, US

International Classification:

A61K 31/496
C07D 401/12
A61K 31/00

Abstract:

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m/g; and crystals of aripiprazole lauroxil produced by such processes.

US Patent:

20200108063, Apr 9, 2020

Filed:

Oct 8, 2019

Appl. No.:

16/595608

Inventors:

- Dublin, IE
Tarek A. Zeidan - Lexington MA, US
Renato A. Chiarella - Cambridge MA, US
Steven G. Wright - Madeira OH, US
Jason M. Perry - Cambridge MA, US

International Classification:

A61K 31/496
C07D 401/12
A61K 31/00

Abstract:

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m/g; and crystals of aripiprazole lauroxil produced by such processes.

US Patent:

20190015408, Jan 17, 2019

Filed:

Jul 24, 2018

Appl. No.:

16/043721

Inventors:

- DUBLIN, IE
Tarek A. Zeidan - Lexington MA, US
Renato A. Chiarella - Cambridge MA, US
Steven G. Wright - Madeira OH, US
Jason M. Perry - Cambridge MA, US

International Classification:

A61K 31/496
C07D 401/12
A61K 31/00

Abstract:

Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m/g; and crystals of aripiprazole lauroxil produced by such processes.

US Patent:

20170312258, Nov 2, 2017

Filed:

Jul 14, 2017

Appl. No.:

15/650437

Inventors:

- Lexington MA, US
Diana Manzanedo - Cambridge MA, US
Jason M. Perry - Cambridge MA, US
Wesley Dehaan - Chelmsford MA, US
Brian Trautman - Arlington MA, US

International Classification:

A61K 31/439
A61K 31/58
A61K 31/57
A61K 9/16
A61K 9/16
A61K 45/06
A61K 9/00

Abstract:

The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise about 79.5% to about 80.5% (w/w) sodium chloride, about 19.5% to about 20.5% (w/w) leucine, and about 0.01% to about 0.5% (w/w) tiotropium bromide, and methods for treating a subject using the respirable dry powders.

US Patent:

20170317999, Nov 2, 2017

Filed:

Apr 27, 2016

Appl. No.:

15/139750

Inventors:

- San Jose CA, US
Yedidya Dotan - Newton MA, US
Christopher Duane - Groton MA, US
Jason M. Perry - Plymouth MA, US

International Classification:

H04L 29/06
G06F 9/44
H04L 29/06
H04L 29/08

Abstract:

Presented herein are techniques for remotely releasing bootstrap credentials to a cloud management proxy device. In particular, a cloud management proxy device that is associated with a cloud system commences a boot operation. The cloud management proxy device then initiates a remote credential release process to obtain the bootstrap credentials, which are useable by the cloud management proxy device to complete the boot operation. Upon completion of the remote credential release process, the bootstrap credentials are received from a remote credential manager system.

US Patent:

20170304197, Oct 26, 2017

Filed:

Oct 7, 2015

Appl. No.:

15/517724

Inventors:

- Lexington MA, US
Jason M. Perry - Cambridge MA, US
Michael Tauber - Allston MA, US

Assignee:

PULMATRIX OPERATING COMPANY, INC. - Lexington MA

International Classification:

A61K 9/00
C07D 333/10
A61K 31/58
A61K 31/46
A61K 31/439
C07D 419/14
A61K 9/14

Abstract:

A dry powder containing dry particles that contain a tiotropium salt, one or more amino acids, and acid content, and optionally, sodium chloride, and/or one or more additional therapeutic agents, wherein the molar ratio of acid to amino acid is from about 0.0005 to about 5, or 0.002 to about 1. In one aspect, the dry powder containing dry particles is suitable for administration to the respiratory tract. In one aspect, the dry powder containing dry particles is a respirable dry powder contains respirable dry particles that contain a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or ore additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the leucine is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to amino acid is from about 0.002 to about 1, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.

US Patent:

20170304198, Oct 26, 2017

Filed:

Oct 7, 2015

Appl. No.:

15/517728

Inventors:

- Lexington MA, US
Jason M. Perry - Cambridge MA, US
Michael Tauber - Allston MA, US

International Classification:

A61K 9/00
A61K 33/14
A61K 31/381
A61K 31/439
A61K 47/18
A61K 45/06

Abstract:

The invention relates to, for example, a respirable dry powder that contains respirable dry particles that contains a tiotropium salt, one or more amino acids, sodium chloride, and optionally one or more additional therapeutic agents, where the tiotropium salt is about 0.01% to about 0.5%, the one or more amino acids is about 5% to about 40%, the sodium chloride is about 50% to about 90%, and the optional one or more additional therapeutic agents are up to about 30%, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein the majority of the one or more amino acids are present in a crystalline state.